Allogeneic stem cell transplantation for Fanconi anaemia

Ph Guardiola, G. Socié, R. Pasquini, I. Dokal, J. J. Ortega, M. Van Weel-Sipman, J. Marsh, F. Locatelli, G. Souillet, J. Y. Cahn, P. Ljungman, R. Miniero, J. Shaw, Ch Vermylen, E. Archimbaud, A. N. Bekassy, G. Krivan, P. Di Bartolomeo, A. Bacigalupo, E. Gluckman

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Fanconi anaemia is a hereditary disorder characterised by chromosomal breaks increased by cross-linking agents. Bone marrow transplantation is the treatment of choice when a HLA identical sibling donor has been identified. The use of low-dose cyclophosphamide with thoraco-abdominal irradiation for the conditioning regimen of FA patients has lead to a dramatic improvement of survival, with a long-term survival of 75% at our institution. However, if most patients are completely cured of their haematological disease, there is concern about an increased frequency of secondary tumours, mostly head and neck squamous cell carcinomas of poor prognosis. Results of BMT using alternative donors (HLA mismatched related and unrelated donors) have also improved during the last decade. A better selection of the donor via high-resolution techniques for class-II HLA matching, and more recently the use of T cell depleted grafts are probably the main explanations. Despite a short follow-up and the small number of patients analysed, transplants using HLA matched family cord blood give some promising results. On the other hand, first results with unrelated cord blood remind that this approach is clearly an experimental one that has to be evaluated through international registries and prospective studies. New approaches including autologous stem cell transplantations and gene therapy are currently explored.

Original languageEnglish
JournalBone Marrow Transplantation
Volume21
Issue numberSUPPL. 2
Publication statusPublished - Apr 1998

Fingerprint

Fanconi Anemia
Stem Cell Transplantation
Fetal Blood
Tissue Donors
Transplants
Donor Selection
Chromosome Breakage
Unrelated Donors
Survival
Hematologic Diseases
Cell- and Tissue-Based Therapy
Bone Marrow Transplantation
Genetic Therapy
Cyclophosphamide
Registries
Siblings
Prospective Studies
T-Lymphocytes
Neoplasms
Therapeutics

Keywords

  • Allogeneic bone marrow transplantation
  • Alternative donors
  • Aplastic anaemia
  • Cord blood
  • Fanconi anaemia
  • Secondary malignancies
  • T cell depletion

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Guardiola, P., Socié, G., Pasquini, R., Dokal, I., Ortega, J. J., Van Weel-Sipman, M., ... Gluckman, E. (1998). Allogeneic stem cell transplantation for Fanconi anaemia. Bone Marrow Transplantation, 21(SUPPL. 2).

Allogeneic stem cell transplantation for Fanconi anaemia. / Guardiola, Ph; Socié, G.; Pasquini, R.; Dokal, I.; Ortega, J. J.; Van Weel-Sipman, M.; Marsh, J.; Locatelli, F.; Souillet, G.; Cahn, J. Y.; Ljungman, P.; Miniero, R.; Shaw, J.; Vermylen, Ch; Archimbaud, E.; Bekassy, A. N.; Krivan, G.; Di Bartolomeo, P.; Bacigalupo, A.; Gluckman, E.

In: Bone Marrow Transplantation, Vol. 21, No. SUPPL. 2, 04.1998.

Research output: Contribution to journalArticle

Guardiola, P, Socié, G, Pasquini, R, Dokal, I, Ortega, JJ, Van Weel-Sipman, M, Marsh, J, Locatelli, F, Souillet, G, Cahn, JY, Ljungman, P, Miniero, R, Shaw, J, Vermylen, C, Archimbaud, E, Bekassy, AN, Krivan, G, Di Bartolomeo, P, Bacigalupo, A & Gluckman, E 1998, 'Allogeneic stem cell transplantation for Fanconi anaemia', Bone Marrow Transplantation, vol. 21, no. SUPPL. 2.
Guardiola P, Socié G, Pasquini R, Dokal I, Ortega JJ, Van Weel-Sipman M et al. Allogeneic stem cell transplantation for Fanconi anaemia. Bone Marrow Transplantation. 1998 Apr;21(SUPPL. 2).
Guardiola, Ph ; Socié, G. ; Pasquini, R. ; Dokal, I. ; Ortega, J. J. ; Van Weel-Sipman, M. ; Marsh, J. ; Locatelli, F. ; Souillet, G. ; Cahn, J. Y. ; Ljungman, P. ; Miniero, R. ; Shaw, J. ; Vermylen, Ch ; Archimbaud, E. ; Bekassy, A. N. ; Krivan, G. ; Di Bartolomeo, P. ; Bacigalupo, A. ; Gluckman, E. / Allogeneic stem cell transplantation for Fanconi anaemia. In: Bone Marrow Transplantation. 1998 ; Vol. 21, No. SUPPL. 2.
@article{e58d9c91d0244921ae0726fe6109fd1f,
title = "Allogeneic stem cell transplantation for Fanconi anaemia",
abstract = "Fanconi anaemia is a hereditary disorder characterised by chromosomal breaks increased by cross-linking agents. Bone marrow transplantation is the treatment of choice when a HLA identical sibling donor has been identified. The use of low-dose cyclophosphamide with thoraco-abdominal irradiation for the conditioning regimen of FA patients has lead to a dramatic improvement of survival, with a long-term survival of 75{\%} at our institution. However, if most patients are completely cured of their haematological disease, there is concern about an increased frequency of secondary tumours, mostly head and neck squamous cell carcinomas of poor prognosis. Results of BMT using alternative donors (HLA mismatched related and unrelated donors) have also improved during the last decade. A better selection of the donor via high-resolution techniques for class-II HLA matching, and more recently the use of T cell depleted grafts are probably the main explanations. Despite a short follow-up and the small number of patients analysed, transplants using HLA matched family cord blood give some promising results. On the other hand, first results with unrelated cord blood remind that this approach is clearly an experimental one that has to be evaluated through international registries and prospective studies. New approaches including autologous stem cell transplantations and gene therapy are currently explored.",
keywords = "Allogeneic bone marrow transplantation, Alternative donors, Aplastic anaemia, Cord blood, Fanconi anaemia, Secondary malignancies, T cell depletion",
author = "Ph Guardiola and G. Soci{\'e} and R. Pasquini and I. Dokal and Ortega, {J. J.} and {Van Weel-Sipman}, M. and J. Marsh and F. Locatelli and G. Souillet and Cahn, {J. Y.} and P. Ljungman and R. Miniero and J. Shaw and Ch Vermylen and E. Archimbaud and Bekassy, {A. N.} and G. Krivan and {Di Bartolomeo}, P. and A. Bacigalupo and E. Gluckman",
year = "1998",
month = "4",
language = "English",
volume = "21",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation for Fanconi anaemia

AU - Guardiola, Ph

AU - Socié, G.

AU - Pasquini, R.

AU - Dokal, I.

AU - Ortega, J. J.

AU - Van Weel-Sipman, M.

AU - Marsh, J.

AU - Locatelli, F.

AU - Souillet, G.

AU - Cahn, J. Y.

AU - Ljungman, P.

AU - Miniero, R.

AU - Shaw, J.

AU - Vermylen, Ch

AU - Archimbaud, E.

AU - Bekassy, A. N.

AU - Krivan, G.

AU - Di Bartolomeo, P.

AU - Bacigalupo, A.

AU - Gluckman, E.

PY - 1998/4

Y1 - 1998/4

N2 - Fanconi anaemia is a hereditary disorder characterised by chromosomal breaks increased by cross-linking agents. Bone marrow transplantation is the treatment of choice when a HLA identical sibling donor has been identified. The use of low-dose cyclophosphamide with thoraco-abdominal irradiation for the conditioning regimen of FA patients has lead to a dramatic improvement of survival, with a long-term survival of 75% at our institution. However, if most patients are completely cured of their haematological disease, there is concern about an increased frequency of secondary tumours, mostly head and neck squamous cell carcinomas of poor prognosis. Results of BMT using alternative donors (HLA mismatched related and unrelated donors) have also improved during the last decade. A better selection of the donor via high-resolution techniques for class-II HLA matching, and more recently the use of T cell depleted grafts are probably the main explanations. Despite a short follow-up and the small number of patients analysed, transplants using HLA matched family cord blood give some promising results. On the other hand, first results with unrelated cord blood remind that this approach is clearly an experimental one that has to be evaluated through international registries and prospective studies. New approaches including autologous stem cell transplantations and gene therapy are currently explored.

AB - Fanconi anaemia is a hereditary disorder characterised by chromosomal breaks increased by cross-linking agents. Bone marrow transplantation is the treatment of choice when a HLA identical sibling donor has been identified. The use of low-dose cyclophosphamide with thoraco-abdominal irradiation for the conditioning regimen of FA patients has lead to a dramatic improvement of survival, with a long-term survival of 75% at our institution. However, if most patients are completely cured of their haematological disease, there is concern about an increased frequency of secondary tumours, mostly head and neck squamous cell carcinomas of poor prognosis. Results of BMT using alternative donors (HLA mismatched related and unrelated donors) have also improved during the last decade. A better selection of the donor via high-resolution techniques for class-II HLA matching, and more recently the use of T cell depleted grafts are probably the main explanations. Despite a short follow-up and the small number of patients analysed, transplants using HLA matched family cord blood give some promising results. On the other hand, first results with unrelated cord blood remind that this approach is clearly an experimental one that has to be evaluated through international registries and prospective studies. New approaches including autologous stem cell transplantations and gene therapy are currently explored.

KW - Allogeneic bone marrow transplantation

KW - Alternative donors

KW - Aplastic anaemia

KW - Cord blood

KW - Fanconi anaemia

KW - Secondary malignancies

KW - T cell depletion

UR - http://www.scopus.com/inward/record.url?scp=0031949423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031949423&partnerID=8YFLogxK

M3 - Article

VL - 21

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL. 2

ER -